CD274 and neoplasm: The combination of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies like nivolumab or pembrolizumab) with targeted therapies may offer benefits, as the tumor could be more prone to immune evasion mechanisms due to its molecular profile.